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Abstract
Human mesenchymal stem cells (hMSCs) are adult multipotent stem cells located in various tissues, including the bone marrow. In contrast to
terminally differentiated somatic cells, adult stem cells must persist and function throughout life to ensure tissue homeostasis and repair. For
this reason, they must be equipped with DNA damage responses able to maintain genomic integrity while ensuring their lifelong persistence.
Evaluation of hMSC response to genotoxic insults is of great interest considering both their therapeutic potential and their physiological func-
tions. This study aimed to investigate the response of human bone marrow MSCs to the genotoxic agent Actinomycin D (ActD), a well-known
anti-tumour drug. We report that hMSCs react by undergoing premature senescence driven by a persistent DNA damage response activation,
as hallmarked by inhibition of DNA synthesis, p21 and p16 protein expression, marked Senescent Associated b-galactosidase activity and
enlarged cH2AX foci co-localizing with 53BP1 protein. Senescent hMSCs overexpress several senescence-associated secretory phenotype
(SASP) genes and promote motility of lung tumour and osteosarcoma cell lines in vitro. Our findings disclose a multifaceted consequence of
ActD treatment on hMSCs that on the one hand helps to preserve this stem cell pool and prevents damaged cells from undergoing neoplastic
transformation, and on the other hand alters their functional effects on the surrounding tissue microenvironment in a way that might worsen
their tumour-promoting behaviour.
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Introduction
Human bone marrow mesenchymal stem cells (hMSCs) are adult
multipotent stem cells with the capacity of self-renewal and ability to
differentiate into adipogenic, chondrogenic and osteogenic lineages
[1]. The endogenous role for hMSCs is maintenance of stem cell
niches (classically the haematopoietic), and as such, hMSCs partici-
pate in organ homeostasis, wound healing and successful ageing [2].
The potential of hMSCs to maintain multipotency and proliferate
extensively in vitro also provides new avenues for cell-based therapy
in the restoration of damaged or diseased tissue and, currently, the
numbers of clinical trials that employ MSCs are increasing [3, 4]. In
the light of their physiological functions and therapeutic potential, the
evaluation of hMSC response to genotoxic insults is of great interest.
Most of the established anti-cancer therapies cause various levels
of DNA damage; cells respond through the activation of the DNA dam-
age response (DDR) pathways that regulate cell cycle arrest and DNA
repair. Generally, if DNA repair is ineffective, cells either undergo
apoptosis or become senescent [5, 6]. The choice between these
three outcomes is crucial for adult stem cells as it can dramatically
impact on their pool preservation and functional features.
Actinomycin D (ActD) is a well-known antibiotic with anti-tumour
activity, widely used for treating both adult neoplasms (i.e. gestational
trophoblastic disease) and several paediatric malignant tumours
(i.e. Wilms’ tumour, retinoblastoma, rhabdomyosarcoma, Ewing’s
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sarcoma). Its biological activity is related to the ability to bind to the
DNA duplex with high affinity, thereby interfering with transcription
and replication [7]. ActD was shown to accumulate in nucleated cells,
such as bone marrow and tumour cells, to substantially greater con-
centrations than in plasma at corresponding times [8]. We previously
showed that ActD produces unrepairable DNA damage in both periph-
eral blood mononuclear cells and T cells from normal individuals [9],
inducing their death via an ATM- and p53-dependent apoptotic path-
way [9, 10], but no data regarding ActD effects on adult stem cells,
including hMSCs, are yet available.
Notably, hMSCs showed to be highly resistant to apoptosis
induced by different genotoxic insults [11–17], even though the pre-
cise resistance mechanisms are not completely understood. Recently
it has been reported that another possible response of hMSCs to
injury is stress-induced premature senescence (SIPS) [18–24]. Even
if SIPS represents an important tumour suppressive mechanism that
irreversibly prevents damaged cells from undergoing neoplastic
transformation, it is clearly a double-edged sword [25]. Senescent
cells, indeed, develop the so-called senescence-associated secretory
phenotype (SASP) [26, 27], which is an altered secretory activity, that
may induce changes in the tissue microenvironment in ways that can
promote both cancer and ageing phenotypes [28, 29].
This study aimed at investigating the molecular, cellular and func-
tional changes induced in bone marrow-derived hMSCs by ActD treat-
ment. We report that hMSCs react to this genotoxic insult by
undergoing SIPS rather than apoptosis; that SIPS is induced by a per-
sistent DDR activation hallmarked by enlarged cH2AX foci co-localiz-
ing with 53BP1 protein; that SIPS results in an overexpression of
several SASP genes; and finally, that SIPS increases the capacity of
hMSCs to promote motility of lung tumour and osteosarcoma cell
lines in vitro. The present results underline a multifaceted response of
hMSCs to ActD that might alter their functional effects on the
surrounding tissue microenvironment.
Materials and methods
Cell culture and drug treatment
U2OS and CALU-1 cell lines were purchased from ATCC. hMSCs were
obtained from Lonza Group (Walkersville, MD, USA), routinely expanded
seeding at a density of 3500 cell/cm2 and subcultured twice a week.
Exponentially growing hMSCs were seeded at 7000 cell/cm2 24 hrs
before genotoxic treatment. To minimize the effects of replicative senes-
cence, hMSCs at early passages (p4–p7) were used. Adherent cells
were cultured in complete DMEM (1000 mg/l glucose; Sigma-Aldrich,
St Luis, MO, USA) supplemented with 10% foetal bovine serum (FBS;
Sigma-Aldrich), 2 mM L-Glutamine, 1% kanamycin, 1% sodium pyru-
vate, 1% non-essential amino acids, 0.1% b-mercaptoethanol (all from
Gibco, Gaithersburg, MD, USA).
Peripheral blood from four healthy donors was collected after signed
informed consent. Peripheral blood mononucleated cells were isolated
and T-cell lines were generated as described [30] and used when >95%
of T cells were in G0/G1. T cells were cultured in RPMI supplemented
with 2 mM L-Glutamine, 1% kanamycin, 1% sodium pyruvate, 1%
non-essential amino acids, 0.1% b-mercaptoethanol (all from Gibco),
5% human serum (BioWitthaker, Cambrex, Baltimore, MD, USA),
200 U/ml IL-2 (from the myeloma producing cell line IL2-t6, kindly pro-
vided by Dr A. Lanzavecchia, IRB, Bellinzona, Switzerland).
ActD (A9415; Sigma-Aldrich) was dissolved at 10 lg/ll in DMSO
(D5879; Sigma-Aldrich) and used at the final concentration of 0.5 lg/ml
(400 mM) in complete medium. Cells treated with DMSO, diluted
1:20,000, were used as control. After 3 hrs of incubation, medium sup-
plemented with ActD/DMSO was removed and cells were washed three
times with PBS before being cultured in fresh complete medium for dif-
ferent recovery times. During long recovery times, medium was chan-
ged every 2–3 days to ActD-treated cells, whereas control cells were
reseeded at a density of 3500 cells/cm2 to avoid overconfluence.
Cell viability assay
Cell viability was evaluated by propidium iodide (PI) staining at 24, 48
and 72 hrs of recovery after cell treatment. Briefly, cells were col-
lected, resuspended in PBS at 106cells/ml and stained with 1 lg/ml PI
for 5 min. at RT in the dark. At least 30,000 cells for each experimen-
tal point were acquired on a Cyan ADP flow cytometer (Beckman Coul-
ter, Brea, CA, USA) and analysed with Summit 4.0 software. Viable
cells were expressed as percentage of living cells, evaluated on PE-log
versus FS-Lin plots, normalized respect to the relative time-point
control.
EdU staining
Human mesenchymal stem cells were seeded on l-Slide 8 well ibitreat
(Ibidi, Martinsried, Munich, Germany), treated with 2.5 lg/ml 5-ethynyl-
20-deoxyuridine (EdU) for 3 hrs and stained with the Click-iT EdU
Imaging kit (Molecular Probes Inc., Eugene, OR, USA), following the
manufacturer’s instructions. Briefly, hMSCs were fixed with 3.7% form-
aldehyde in PBS, permeabilized with 0.5% Triton X-100 and stained for
30 min. at RT in the dark with the Click-iT reaction cocktail. hMSCs
were then washed with PBS and stained with 5 lg/ml Hoechst 33342,
for 20 min. in the dark, washed twice in PBS, mounted with Mowiol
solution (Calbiochem, San Diego, CA, USA) and then analysed with 510
Carl Zeiss confocal laser microscope by using a 109 objective.
Multipotent differentiation
For induction of either osteogenic or adipogenic differentiation, hMSCs
were seeded at 30,000 cells/cm2. After 24 hrs of recovery from drug
treatment, they were incubated in a differentiation medium for several
weeks, with the medium being changed every 2–3 days. The osteogenic
differentiation medium was as follows: DMEM 1000 mg/l glucose sup-
plemented with 10% heat-inactivated FBS, 1% non-essential amino
acids, 1% glutamine, 1% kanamycin (all from Gibco), 100 nM dexa-
methasone, 0.2 mM ascorbic acid 2-phosphate and 10 mM b-glycero-
phosphate (all from Sigma-Aldrich).
To detect mineralization (calcium deposits), 3 weeks after induction
cells were fixed with ice-cold 70% ethanol and stained with 40 mM Aliz-
arin Red S (Sigma-Aldrich). Images were taken with Motic AE2000
phase contrast microscope at 109 magnification. For adipogenic
differentiation, the complete DMEM medium was supplemented with
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10 lg/ml insulin, 1 lM dexamethasone, 0.5 mM 3-isobutyl-1-methyl-
xanthine and 100 lM indomethacin (all from Sigma-Aldrich). To detect
fat deposition, 2 weeks after induction cells were fixed with 10% forma-
line buffered solution for 1 hr at RT and stained with Oil Red O (Sigma-
Aldrich). Images were taken with Motic AE2000 phase contrast micro-
scope at 209 magnification.
Senescence-associated b-galactosidase
(SA-b-Gal) assay
Cell staining for b-galactosidase activity was performed as previously
described by Debacq-Chainiaux et al. [31]. The percentage of SA-b-
Gal-positive cells was calculated by counting at least 1000 cells.
Protein extracts and immunoblotting
Human mesenchymal stem cells were collected, washed with PBS, pel-
leted and lysed in Laemmli buffer (125 mM Tris-HCl pH 6.8, 5% SDS).
Samples were boiled for 2 min. and, after chilling, Complete Mini prote-
ase inhibitor cocktail and PhosSTOP phosphatase inhibitor cocktail
(Roche, Indianapolis, IN, USA) were added. Samples were then soni-
cated and centrifuged at 14,000 r.p.m. for 10 min. Protein content was
determined by the micro-bicinchoninic acid method (Thermo Scientific,
Rockford, IL, USA) and 20 lg of each total cell lysate were size frac-
tionated by SDS-PAGE 3–8% gels (Invitrogen, Carlsbad, CA, USA) and
electroblotted onto PVDF membranes (Amersham, GE Healthcare, Buck-
inghamshire, UK). After blocking with either 5% (wt/vol) non-fat dried
milk in PBS plus 0.1% (vol/vol) Tween-20 (Sigma-Aldrich-Co.) or 5%
(wt/vol) bovine serum albumin (BSA) in Tris-buffered saline, pH 7.5, the
membranes were incubated with the following primary antibodies:
mouse monoclonal antibodies against p53 1:1000 (clone DO7, Santa
Cruz), phospho-p53(Ser15) 1:1000 (Cell Segnaling), b-actin 1:4000
(clone AC-74, Sigma-Aldrich), vinculin 1:4000 (clone HVIN-1, Sigma-
Aldrich); rabbit monoclonal antibody against p16INK4A 1:1000 (clone
EPR1473; Abcam, Cambridge, UK) and rabbit polyclonal antibody
against p21 1:1000 (ab7960; Abcam). The secondary antibodies used
include horseradish-conjugated goat anti-rabbit (Abcam) and horserad-
ish-conjugated rabbit anti mouse (Abcam) (both 1:10,000). Immunore-
active bands were visualized by ECL Super Signal (Thermo Scientific)
on autoradiographic films.
Immunofluorescence
Human mesenchymal stem cells were plated on l-Slide 8 well ibitreat
(Ibidi, Martinsried, Germany), fixed with 4% paraformaldehyde, permea-
bilized with 1% Triton X-100 and blocked with 6% (wt/vol) BSA
(Sigma-Aldrich) and 2.5% (vol/vol) normal goat serum (Sigma-Aldrich).
Cells were then stained with the following primary antibodies: mouse
monoclonal antibodies anti-phospho-Histone H2AX(Ser139) 1:500
(clone JBW301; Millipore, Billerica, MA, USA) and anti-ATMpS1981
1:300 (clone 10H11.E12, Rockland) or rabbit polyclonal antibody
against 53BP1 1:500 (Novus Biological, Cambridge, UK) for 2 hrs at
4°C. Secondary antibodies were: Alexa 488 or Alexa 546 conjugated
goat anti mouse and Alexa 546 conjugated goat anti-rabbit (all
1:500; Molecular Probes Inc.). Nuclei were stained with 0.1 lg/ml
40-6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) and slides
mounted by using Mowiol solution (Calbiochem). Fluorescence images
were obtained with a TCS-SPE, Leica Microsystem at 639 magnifica-
tion. cH2AX foci quantification was performed counting at least 300
cells for each time-point.
RNA extraction, cDNA synthesis and real-time
PCR
Human mesenchymal stem cells were dissolved in TRIzol reagent (Life
Technologies) and total RNA (totRNA) was extracted according to the
manufacturer’s instructions. Genomic DNA contaminations were removed
by DnaseI treatment (Ambion, USA) and RNA was then quantified. One
microgram of totRNA was finally retrotranscribed with random hexamer
primers and Multiscribe Reverse Transcriptase contained in High Capacity
Reverse Transcription Kit (Applied Biosystems, USA) in accordance with
manufacturer’s suggestions. Expression levels of nine SASP genes (GM-
CSF, GRO1, ICAM1, IL-6, IL-8, MCP-2, MMP3, RANTES and SDF1) were
evaluated with SYBR green technology on an ABI PRISM 7500 Fast Real-
Time PCR system (Applied Biosystems) by using 25 ng of cDNA template
and 150 lM of each primer. Melting curve analysis was routinely per-
formed to check for the presence of a single peak corresponding to the
required amplicon. For each target gene, relative variation of transcript
levels in ActD-treated hMSCs was evaluated with the DDCt method by
using Actb as reference gene and time-matched DMSO-treated cells as
calibrators. The primers used are listed in Table S1.
Generation of conditioned medium, migration
assay and proliferation assay
To generate hMSC-conditioned medium (hMSC-CM) from both control
(DMSO-treated) and senescent (ActD-treated) cells, hMSCs were cul-
tured for 24 hrs in DMEM supplemented with either 2% FBS for the
migration assay or 10% FBS for the proliferation assay; then the CM
was collected, spun down to remove cell debris (3000RPM for 10 min.)
and passed through a 0.22 lm filter. CM aliquots were flash frozen in
liquid nitrogen and stored at 80°C until required. For the migration
assay, the lower chambers of 24-well systems were filled with 700 ll
hMSC-CM; 100,000 CALU-1 or U2OS cells resuspended in 200 ll of
2% FBS DMEM were seeded in the upper part of the cell culture insert
on a porous transparent polyethylene terephthalate membrane (8 lm
pore size, 105 pores/cm2; #353097; Becton Dickinson Biosciences). The
multiwells containing the cell culture inserts were incubated at 37°C in
a humidified 5% CO2 atmosphere; migration assay was carried out for
4.5 hrs (CALU-1) and 16 hrs (U2OS). Afterwards, culture inserts were
rinsed with PBS and cells attached to the upper side of the membrane
were mechanically removed by using a cotton-tipped applicator. Cells
that migrated to the lower side of the membrane were fixed with 2%
glutaraldehyde for 20 min., washed five times in water, stained 20 min.
in 0.1% cristal violet, 20% methanol, washed five times in water and
air-dried. For each cell insert, three images at 2.59 magnification were
taken with a Leica DC100 phase contrast microscope and counted by
using ImageJ software (Rasband, W.S., ImageJ, U. S. National Insti-
tutes of Health, Bethesda, MD, http://rsb.info.nih.gov/ij/, 1997–2013).
The migration assay was performed in three independent experiments.
For the proliferation assay, U2OS and CALU-1 cells were plated in
triplicate at a density of 15,000 cells per well in 24-well plates. After
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overnight seeding, 500 ll of CM (either control or senescent hMSCs-
CM) were added, tumour cells cultured for 48 hrs and their proliferation
assessed by using the CellTiter-Blue Cell Viability Assay (Promega,
USA). Fluorescence emission was read at 590 nm with a multi-plate
reader (Infinite F200, Tecan, Switzerland).
Statistical analysis
Data are represented as mean  SD. For statistical analysis Student’s
t-test was performed and the significance was expressed with asterisks:
*P < 0.05; **P < 0.01; ***P < 0.005.
Results
hMSCs are resistant to ActD-induced cell death
The survival of multipotent hMSCs following 3 hrs of ActD (400 mM)
treatment was evaluated respect to two sensitive cell lines, differenti-
ated-resting T cells [9] and the neoplastic-cycling osteosarcoma
U2OS cell line [32, 33].
ActD induced an evident and significant cell death of both sensi-
tive lines, with survival rates of 2.7%  1.5% (T cells) and 10.1%
2.0 (U2OS) at 72 hrs. In contrast, hMSCs were resistant to ActD
treatment with a survival rate of 87.6%  5.2% at 72 hrs (Fig. 1A).
ActD induced a DDR response in hMSCs as demonstrated by
autophosphorylation of ATM in Ser1981 and phosphorylation of p53
in Ser15 detected by immunofluorescence and western blotting
respectively (Fig. 1B and C). The phosphorylation of the histone vari-
ant H2AX on Ser139 (cH2AX), an early and specific marker of DNA
damage, was then assessed. Immunofluorescence analysis showed
that ActD treatment strongly induced cH2AX foci in hMSCs with
almost 90% of cells carrying a number of foci comprised between 31
and 100 at 3 hrs of treatment (Fig. 1D and E). After 24 hrs of recov-
ery, only 6% of hMSCs had become completely negative for cH2AX,
while the majority of cells still carried a number of foci comprised
between 1 and 30 (Fig. 1D and E). At this time-point a small fraction
of cells (less than 7%) had more than 100 foci (Fig. 1E), an event that
could be ascribed to a small degree of apoptotic DNA fragmentation
[34]; accordingly, at 24 hrs of recovery about 8% of treated cells
were found to be annexin V-positive/PI-negative, i.e. early apoptotic
(data not shown).
Despite the presence of unresolved cH2AX foci at 24 hrs of recov-
ery, hMSCs are still able to differentiate towards the osteogenic and
adipogenic lineages. Indeed, after incubation with the respective
induction media, both control and ActD-treated hMSCs showed the
typical signs of osteogenic and adipogenic differentiation: extracellu-
lar calcium deposits that stained positive by alizarin red (Fig. 1F, to
panel) and intracellular lipid droplets that stain positive by oil red
(Fig 1F, bottom panel).
Taken together, these data demonstrate that hMSCs survive to
ActD-induced DNA damage, respond with a quick and strong activa-
tion of the DDR pathway and retain their multipotent features, yet they
maintain a considerable number of unresolved cH2AX foci.
ActD-treated hMSCs undergo SIPS following a
persistent DDR activation
Considering that DNA damage accumulation could result in SIPS
[35], analyses were carried on to investigate if ActD-treated hMSCs
underwent senescence.
As growth arrest is an hallmark of senescence, the inhibition of
DNA synthesis was evaluated through EdU incorporation staining.
After ActD treatment, a strong reduction of hMSCs in active DNA syn-
thesis was observed already on day 1, with only 16% EdU positive
cells, compared to 46% of EdU positivity detected in control cells.
DNA synthesis was then completely abolished in ActD-treated cells by
day 9 (Fig. 2A).
Next, protein expression changes compatible with senescence
induction were studied by immunoblotting during a 9-day interval
(Fig. 2B). p53 amount markedly increased soon after ActD treatment,
it reached a maximum on day 3 and then started to decrease; after
9 days, the amount of p53 in ActD-treated cells was still slightly
greater than in control cells (Fig. 2B). Expression of the p53 respon-
sive protein p21 protein, an inhibitor of the cyclin-dependent kinase
1A, was clearly detectable on day 1, reached its maximum on day 2
and subsequently gradually decreased (Fig. 2B). Contemporarily to
p21 decrease, the amount of p16, an inhibitor of cyclin-dependent
kinases 4 and 6, increased and reached its maximum on day 6
(Fig. 2B).
To further confirm senescence induction in ActD-treated hMSCs,
the activity of SA-b-gal was evaluated. On day 3, the majority of ActD-
treated cells were larger and more flattened compared with control
hMSCs, which maintained a spindle-shaped, fibroblast-like morphol-
ogy (data not shown). After 9 days, ActD-treated cells showed a
marked SA-b-gal activity (55.3%  6.3%) compared with the con-
trols (5.8%  2.3%; data not shown). The percentage of b-gal
stained cells increased with time and reached its maximum after
21 days (84.7%  4.7% positive cells in ActD-treated cells versus
18%  1.2% positive cells in the controls; Fig. 2C).
It has been reported that damaged senescent cells harbour char-
acteristic enlarged and persistent DNA damage nuclear foci (PDDF)
that contain DDR proteins, including cH2AX and 53BP1 [36, 37]. In
accordance, the presence of PDDF in ActD-treated hMSCs was
observed: after 21 days of recovery about 50% of cells contained a
number of cH2AX foci comprised between 1 and 10 (Fig. 2D), that
completely co-localized with 53BP1 foci (Fig. 2E). These results
strongly indicate that ActD treatment leads to a persistent DDR activa-
tion that causes SIPS in hMSCs.
Senescent hMSCs display a SASP phenotype and
promote tumour cell migration
Senescent cells increase the expression and secretion of numerous
cytokines, chemokines matrix metalloproteinases and other proteins,
the so-called SASP (reviewed [38]). Considering that gene expression
profiles of senescent cells determined by transcript analysis resemble
the profiles of secreted proteins [26, 39], the expression of nine SASP
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genes (GM-CSF, GRO1, ICAM1, IL-6, IL-8, MCP-2, MMP3, RANTES
and SDF1) was analysed in senescent hMSCs after 9 and 15 days
from ActD treatment. All genes, with the exception of SDF1, greatly
increased their expression compared to control cells (Log2(fold
change) ranging from 2.37 to 8.74) (Fig. 3A).
Subsequently, the influence of hMSC-conditioned medium
(hMSC-CM) of senescent and control cells on the motility and prolif-
eration of two solid tumour-derived cell lines was investigated. Condi-
tioned medium of senescent hMSC enhanced the cell migration ability
of U2OS and CALU-1 by 2.0 and 1.7-folds, respectively, compared
A
B
C
D
E
F
Fig. 1 hMSCs are resistant to ActD-induced DNA damage. (A) Survival of ActD-treated cells was analysed by PI staining and flow cytometry. Cells
were treated for 3 hrs with ActD (400 mM) and allowed to recovery in drug-free medium for 24, 48 and 72 hrs. Values were normalized on control
cells and represented as mean  SD of three independent experiments. Student’s T-test was performed and the significance values indicated by
asterisks. (B) Immunoblotting of total and phosphoSer15-p53 in hMSCs after 3 hrs of ActD treatment and after 24 hrs of recovery. Vinculin was
used as loading control; sign (-) indicates control cells. (C) Immunofluorescence of ATM autophosphorylation in Ser1981 (ph-ATM) in hMSCs after
3 hrs of ActD treatment. (D) Immunofluorescence of cH2AX (red) foci induction in hMSCs after 3 hrs of ActD treatment and of residual foci after
24 hrs of recovery. DAPI counterstains the nuclei (blue). (E) cH2AX foci number quantification in ActD-treated hMSCs; one representative experi-
ment out of two is shown. (F) Control and ActD-treated hMSCs were induced to differentiate after 24 hrs of recovery. Top panel: Alizarin Red S
staining for calcium deposition after 21 days’ culture. 109 magnification images were taken with a contrast phase microscope. Bottom panel: Oil
Red staining for lipid accumulation after 15 days’ culture. 209 magnification images were taken with a contrast phase microscope. In all panels the
white bar represents 10 lm.
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with conditioned medium of control hMSC (Fig. 3B). On the other
hand, CM of senescent hMSCs did not significantly influence prolifer-
ation of these two cell lines (Fig. 3C).
Overall, these data suggest that senescent hMSCs alter their
secretory profile, up-regulating the transcript expression of the two
major inflammatory cytokines involved in SASP and enhancing the
motility of tumour cells.
Discussion
We investigated the molecular, cellular and functional changes
induced in bone marrow-derived hMSCs by the anti-tumour agent
ActD. We show that hMSCs activate the molecular pathway and
exhibit the cellular features of SIPS and that SIPS is induced by
persistent DDR signalling. Functionally, senescent hMSCs over-
express several genes involved in SASP and produce soluble
factors able to promote tumour cell motility in vitro. Our findings
disclose a multifaceted consequence of this chemotherapeutic
treatment on hMSCs that on the one hand helps to preserve this
stem cell pool and prevents damaged cells from undergoing neo-
plastic transformation, yet at the risk of altering hMSC effects on
the surrounding tissue microenvironment.
While ActD had been previously shown to induce unrepairable
DNA damage and to promote prompt apoptosis in cells of haemato-
poietic origin [9], here we found that ActD-treated hMSCs resist
apoptosis and preferentially undergo senescence. Indeed, among the
three established outcomes of the DDR activation (transient cell cycle
arrest coupled with DNA repair, senescence and apoptosis), the first
two appear to be preferable for an adult stem cell allowing at least
partial preservation of the stem cell pool. Along this line, several
in vivo and in vitro data have shown that hMSCs are particularly
resistant to the apoptosis induced by DNA damage [11, 14, 15]. This
resistance to cell death relies on different mechanisms depending on
the different DNA-damaging agents/doses used, including an elevated
apoptosis threshold [16], an efficient antioxidant ROS-scavenging
capacity [13] and a prompt activation of the double strand break
repair pathways [13, 17]. Our results are in accordance with the
more recent literature that described SIPS as a further response of
hMSCs to ionizing radiation [21, 40], oxidative stress [18, 41], heat
shock [19].
One of the main characteristics of SIPS is the accumulation of
persistent cH2AX foci, differing, both in size and persistence, from
the transient foci that occur during initial successful DSB rejoining.
These PDDF have been described in many senescent differentiated
cell types both in vitro and in vivo [36, 37, 42]. Here we describe the
A
B
C
D
E
Fig. 2 hMSCs activate SIPS following ActD
treatment. (A) Percentage of EdU positive
cells on the total Hoechst 33342 positive
cells at 1 and 9 days of recovery after
3 hrs of ActD treatment. Mean  SEM of
three independent experiments is shown.
Student’s t-test was performed and the
significance value indicated by asterisks.
(B) Immunoblotting of p53, p21 and p16
proteins at 0, 1, 2, 3, 6 and 9 days of
recovery. b-Actin was used as loading
control. Sign (-) indicates control cells.
(C) Representative images of b-galactosi-
dase staining after 21 days of recovery
(phase contrast microscope 109 magnifi-
cation images). (D) Immunofluorescence
analysis of persistent cH2AX foci (red)
after 21 days of recovery. DAPI counter-
stains the nuclei (blue). (E) Immunofluo-
rescence co-localization analysis of cH2AX
(green) and 53BP1 (red) after 21 days of
recovery. In all panels the white bar repre-
sents 10 lm.
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presence of PDDF in undifferentiated stem cells and, in accordance
with the observations made in differentiated cells, persistent cH2AX
foci appeared to be characteristically enlarged and completely
co-localized with 53BP1. The significance of PDDF is still debated:
Sedelnikova et al. defined them as cryptogenic nuclear foci containing
unrepairable DSBs [36], while Rodier et al. described them as DNA
Segments with Chromatin Alterations Reinforcing Senescence (DNA-
SCARES) [42]. Moreover, it has been described that changes in
chromatin organization are sufficient to induce senescence and are
associated with increase in H2AX phosphorylation [43, 44]. Irrespec-
tive of their exact nature, we would like to suggest that PDDF
represent another non-canonical role of cH2AX that marks stable
chromatin alterations in senescent cells and should be listed among
the previously described, novel cH2AX roles [45–47].
Despite SIPS is a potent cell-autonomous tumour suppressor
mechanism, the associated SASP, altering the behaviour of neigh-
bouring cells and the quality of tissue environments, exerts cell-non-
autonomous effects than can be either beneficial or detrimental [28].
In fact, senescent cells with persistent DDR signalling show a robust
increase in mRNA levels and protein secretion of numerous cyto-
kines, growth factors and proteases [26, 37, 48], some of which,
like IL6 and IL8, are involved in the reinforcing of the growth arrest
[49, 50] and exert a tumour promoting role [51]. Here, we report
that senescence induced by ActD is coupled with transcriptional up-
regulation of IL-6 and IL-8, as well as several other chemokines
(GRO1, MCP-2, RANTES), inflammatory factors (GM-CSF), metallo-
proteases (MMP3) and adhesion molecules (ICAM1), confirming the
presence of a SASP. The only gene that we did not find up-regulated
is SDF1, a growth factor abundantly expressed by hMSCs. Indeed,
there are variations in quantity and quality of the SASP that might
depend on the cell type and senescence inducer. Albeit SDF1 has
been reported to be up-regulated in senescent prostate stromal
fibroblasts [52, 53], and down-modulated in replicative senescent
hMSCs [54], it is not further regulated in ActD-induced senescent
hMSCs.
The molecular mechanisms mediating SASP genes up-regulation
in hMSCs after the genotoxic stress induced by ActD treatment
are not completely elucidated. The most important transcriptional
A
B
C
Fig. 3 Senescent hMSCs augment the
expression of inflammatory cytokine genes
and promote tumour cell migration. (A)
qPCR relative gene expression levels of
nine SASP factors in ActD-treated hMSCs
after 9 and 15 days of recovery. Relative
variation of transcript levels in ActD-trea-
ted hMSCs was expressed as Log2 (fold
change), calculated by using Actb as ref-
erence gene and time-matched control
cells as calibrator. One representative
experiment out of two. (B) Influence of
conditioned medium obtained from senes-
cent and control hMSCs on the migration
ability of U2OS and CALU-1 cell lines.
Shown are representative images (bottom)
and graph (top) of migrating cell number/
field (mean  SD) derived from three
independent migration assays. Student’s
t-test was performed and the significance
values indicated by asterisks. (C) Influ-
ence of conditioned medium obtained
from senescent and control hMSCs on the
proliferation of U2OS and CALU-1 cell
line. CellTiter-Blue fluorescence values
were normalized on control cells and rep-
resented as mean  SD of three indepen-
dent experiments.
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activator of the SASP is the Nuclear factor (NF)-kB (reviewed in [55]),
whose activation is triggered directly or indirectly by several path-
ways. In particular, following genotoxic stress ATM has been reported
to activate NF-jB signalling via post-translational modification of NF-
jB essential modulator (NEMO) [56, 57]. We here observed a very
early ATM activation in hMSCs upon ActD treatment and some of the
inflammatory cytokines whose mRNA levels were found to be
robustly increased (IL-6, IL-8, ICAM1, CXCL1) were described to be
ATM-dependent [37]. In addition, p53 stabilization/activation was
found to induce release of Alarmin HMGB1 that was essential for opti-
mal secretion of IL-6 and MMP3 [58] and here we described a mark-
edly increased p53 protein in hMSCs during a 9-day interval from
ActD treatment. As for the other up-regulated SASP genes, we can
hypothesize the involvement of other, maybe DDR-independent, path-
ways leading to NF-kB activation, like the one involving p38MAPK that
was found to regulate the SASP largely by increasing NF-kB transcrip-
tional activity independently of the DDR [59].
Senescence-associated secretory phenotype has been shown to
promote the proliferation of pre-malignant and malignant epithelium
[60], enhance invasion [61], induce an epithelial to mesenchymal
transition in carcinoma cells [62], increase the growth of xenograft
tumours in vivo [63] and mediate paracrine transmission of senes-
cence [49]. Nevertheless, all these studies were conducted on senes-
cent fibroblasts. On the other hand, it is well documented that also
mesenchymal stem cells can play tumour-promoting functions [64–
66]. Here we found, for the first time to our knowledge, that senes-
cent hMSCs, altering their secretory profile, enhance the migration of
two solid tumour derived cell lines: U2OS, an osteosarcoma of mes-
enchymal origin [67], and CALU-1, a cell line derived from non-small-
cell lung tumour known to frequently metastasize to the bone [68].
Differently, our in vitro analysis highlighted that CM derived from
senescent hMSC did not significantly affect their proliferation, at least
in the experimental conditions we used. These data suggest that
SASP, induced by ActD treatment, increases the complexity of para-
crine communication among hMSCs and their physiological/patholog-
ical microenvironment, further enhancing their tumour promoting
behaviour.
This is the first time that senescence of an adult stem cell is sug-
gested to enhance its tumour-promoting behaviour. It would be inter-
esting to assess whether this feature can be extended to other adult
stem cells. A greater understanding of the molecular mechanisms
involved in the senescence of hMSCs and careful investigation of the
interconnection among senescent and na€ıve hMSCs secretory pheno-
types will provide valuable new insights to comprehend the link with
this cancer-promoting behaviour. The impact of chemotherapy treat-
ments on the functional behaviour of hMSCs should be carefully con-
sidered with respect to the risk of developing adverse late-occurring
chemotherapy complications. Moreover, the predisposition of hMSCs
to senescence after genotoxic stress should be carefully evaluated in
regenerative approaches that involve in vitro cell expansion or
manipulation.
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